Graviton is developing selective ROCK2 inhibitors for fibrotic and autoimmune indications. The company’s lead asset is GV101, a highly potent and selective ROCK2 inhibitor. It has demonstrated broad therapeutic potential across multiple in-vitro and in-vivo disease models including Graft Versus Host Disease (GVHD) as well as Idiopathic Pulmonary Fibrosis (IPF).
Field:BioPharma
Status:Private
Investors 1
| Date | Name | Website |
| - | Pontifax V... | pontifax.c... |
Mentions in press and media 3
| Date | Title | Description | Source |
| 23.02.2021 | Graviton Enters into Global Licensing Agreement for ROCK2 In... | NEW YORK and BEIJING, Feb. 23, 2021 /PRNewswire/ -- Graviton Bioscience Corporation ("Graviton&... | salamancap... |
| 23.02.2021 | Graviton Enters into Global Licensing Agreement for ROCK2 In... | NEW YORK and BEIJING, Feb. 23, 2021 /PRNewswire/ -- Graviton Bioscience Corporation ("Graviton&... | oaoa.com/n... |
| - | Graviton | - | fastfounde... |